Leila-Sophie Otten
8PUBLICATIONS
23CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Jul 24, 2025
Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer.Fenna de Vries, Leila-Sophie Otten, Berber Piet
|May 27, 2025
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment.Nikki de Rouw, Leila-Sophie Otten, Mart P Kicken
|Jan 28, 2025
Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer.Leila-Sophie Otten, Alessandra I G Buma, Berber Piet
|Jun 11, 2024
Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.Judith L Gulikers, Leila-Sophie Otten, Lizza E L Hendriks
|Oct 19, 2023
Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment.Leila S Otten, Berber Piet, Demy van den Haak
|Apr 01, 2023
Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression.Demy A C van den Haak, Leila-Sophie Otten, Hans J P M Koenen
Pageof 2
Frequent Collaborators
3 joint publications
Berber Piet
2 joint publications
Rob Ter Heine
2 joint publications
Lizza E L Hendriks
1 joint publications
Verena C Mulder
1 joint publications
Demy A C van den Haak
1 joint publications
Judith L Gulikers
1 joint publications
Robin M J M van Geel
1 joint publications
Nikki de Rouw
1 joint publications
Mart P Kicken
1 joint publications
Bonne Biesma
